An Immunological Toolkit for Clinical Application

Lead Research Organisation: Newcastle University
Department Name: Institute of Cellular Medicine

Abstract

Patients with rheumatoid arthritis (RA) suffer with joint pain and stiffness, and joint damage which leads to a reduced ability to carry out everyday tasks. Although these are the most obvious features of the disease, the root cause of the disease lies within the human immune system. At the moment we don?t fully understand the immune abnormalities that lead to RA but, if we did, this should help us to manage the disease better. It would become easier to make a diagnosis, as well as to determine whether a patient?s RA is likely to damage their joints in the future. Perhaps most importantly it would help us to design better drugs to combat the disease, and to better use the drugs that already exist. Something that we would really like to be able to do is to decide the most appropriate drug for each patient and a better understanding of the immune abnormalities would also help here.
Therefore our plans are to study, in detail, the immune system of patients with RA. This will involve taking blood from patients and running a panel of advanced laboratory tests on their white blood cells. We will compare the results we obtain with the immune changes in healthy individuals responding to a vaccine ? expecting some to be the same and some to be different. Our work is in three phases and, during the phases, we plan to slowly ?home in? on simple laboratory tests that will allow us to measure what is happening to the immune system in patients with RA. An exciting aspect of the work is that what is relevant to RA may also relate to other diseases (diabetes, multiple sclerosis, asthma) and to patients with an organ transplant. Therefore our results could have wide-ranging influence beyond improving the care of patients with RA

Technical Summary

Current management of rheumatoid arthritis (RA) is based upon measurement of inflammation and tissue damage. However these are downstream consequences of immune dysregulation, and sub-optimal guides for managing patients and designing disease-modifying drugs. Our aim is to identify the key immune abnormalities that define RA and to develop an immunological toolkit: a set of functional and flow cytometry-based assays to study and monitor the dysfunctional immune system. A UK-wide collaboration of academic and industrial scientists will develop the toolkit, using regular discussions and workshops. Although current theory suggests that key immune abnormalities in RA should reside within T- or B- lymphocytes, lessons from other diseases suggest a discovery approach to be most appropriate, encompassing deep immunophenotyping of major peripheral blood immune and inflammatory cell subsets. Therefore in phase I purified CD4+ and CD8+ T-cells, B-cells, monocytes, NK cells and neutrophils will undergo: multiparameter flow cytometry for cell surface phenotype, intracellular cytokine and lineage transcription factor expression, and signalling pathways; transcriptional analysis using Affymetrix U219 microarrays; and small RNA sequencing. A well-defined subset (n=30) will subsequently undergo ultra-deep RNA sequencing, providing a complete picture of the RA transcriptome. We will study three sets of individuals: 30 healthy controls during an evolving vaccination response; 200 established RA patients, stratified for disease activity and disease duration; and 30 RA patients receiving abatacept (costimulation blockade). Hypothesis-generating phase I will provide a detailed signature of cells and pathways that characterise the RA immune system, and inform the design of customised, low-density array(s) (LDA), alongside the initial development of relevant in vitro immune function assays. In phase II these will be applied to 100 patients with recent onset inflammatory arthritis, sampled longitudinally, alongside a refined panel of flow cytometry protocols. Signals that are consistent between phases I and II will lead to further refinement of the in vitro assays ready for phase III, which encompasses proof-of-concept studies with novel therapeutic compounds, provided by industrial partners. Here the final immune toolkit will be ?road tested?, providing a secondary outcome measure that predicts conventional efficacy parameters. Success in this challenging programme will provide a novel portfolio of immune function assays, potentially applicable to RA but also other immunopathologies. Their widespread adoption and application across diseases will reinforce the successful image of UK translational immunological research. Intellectual property generated by the work will be protected for future exploitation as appropriate.

Organisations

Publications

10 25 50

 
Description A: Arthritis Research UK Disease Subcommittee Meeting, Chesterfield, 2018
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
URL https://www.versusarthritis.org/research/research-funding-and-policy/our-charitable-subcommittees/
 
Description A: CLUSTER Consortium, London 2018 - Stratified Medicine in JIA and associated Uveitis
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://www.arthritisresearchuk.org/research/grant-tracker-items/2018/personalised-treatment-for-chi...
 
Description A: NIHR ARUK Musculoskeletal Experimental Medicine Conference 2018, Nottingham 2018
Geographic Reach National 
Policy Influence Type Participation in a national consultation
URL https://www.arthritisresearchuk.org/research/news-for-researchers/2018/july/maximising-msk-experimen...
 
Description Arthritis Research UK Strategic Workshop - Stacking the Odds Towards a Cure - Versus Arthritis London 2018
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description BBA Forum Meeting London 2016 British Biosimilar Association Clinical Faculty
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Chair - EULAR STUDY GROUP ON THERAPEUTIC DRUG MONITORING OF BIOLOGICS
Geographic Reach Europe 
Policy Influence Type Membership of a guideline committee
URL https://www.eular.org/myUploadData/files/publication_document_therapeutic_drug_monitoring_study_grou...
 
Description Department of Health and Social Care Visit to NIHR Newcastle Biomedical Research Centre - Tony Soteriou
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description MHRA CTBVAG
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description MHRA GRID advisory group
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description MRC Informatics Meeting London 2016
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact MRC Stratified Medicine Leads met to discuss big data and data sharing in medical research.
 
Description MRC Methodology for Stratified Medicine
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description MRC Population and Systems Medicine Board
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description MRC Translational Research Group London 2018
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
URL https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group...
 
Description MRC Translational Research Group, London, 2019
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://mrc.ukri.org/about/our-structure/strategy-board-overview-groups/translational-research-group...
 
Description MRC/ABPI Steering Group
Geographic Reach National 
Policy Influence Type Membership of a guideline committee
 
Description Model collaborative parterships with industry
Geographic Reach National 
Policy Influence Type Citation in other policy documents
 
Description NICE Assessment Sub-Group Meeting for the Diagnostics Assessment Programme, Manchester 2018
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-diagnostics-guidance
 
Description NICE Meeting
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description NIHR BRC Impact Showcase, Newcastle, 2018
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact Influential meeting on Healthy Ageing as a research priority of national importance, as exemplified by our NIHR BRC.
URL https://www.newcastlebrc.nihr.ac.uk/nihr-newcastle-biomedical-research-centre-impact-showcase-presen...
 
Description NIHR Bioresource Meeting
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Newcastle Audit Meeting
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Office for Life Life Sciences Visit (Kristen McLeod)
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Oslo anti-TNF Tendering Meeting 2017
Geographic Reach Europe 
Policy Influence Type Gave evidence to a government review
Impact Tendering meeting to determine anti-TNF tariffs for the next two years. Keynote speaker.
 
Description RT-CURE Regulatory meeting with MHRA, representing RT-CURE regulatory subgroup
Geographic Reach Europe 
Policy Influence Type Participation in a national consultation
URL https://www.rtcure.com/
 
Description TRC Steering Committee, London, 2018 with VA and NOCRI
Geographic Reach National 
Policy Influence Type Participation in a national consultation
 
Description Tocilizumab clinical guidelines for British Society for Rheumatology
Geographic Reach Multiple continents/international 
Policy Influence Type Membership of a guideline committee
URL http://rheumatology.oxfordjournals.org/content/53/7/1344.long
 
Description Translational Research Collaboration for Joint & related inflammatory diseases- Steering Committee Meeting
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
URL http://www.nihr.ac.uk/life-sciences-industry/access-to-expertise-and-collaborations/collaborations-f...
 
Description Wellcome Trust 4WARD Meeting 2016 - Clinical PhD Funding - Newcastle, Leeds, Manchester, Sheffield
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Influenced training of practitioners or researchers
Impact Consortium Clinical PhD Funding Meeting
URL http://www.4wardnorth.org.uk/
 
Description APIPPRA
Amount £66,120 (GBP)
Funding ID BH149466 
Organisation King's College London 
Department School of Medicine KCL
Sector Academic/University
Country United Kingdom
Start 03/2015 
End 02/2019
 
Description Abbvie Investigator initiated funding
Amount £109,465 (GBP)
Funding ID BH137913 
Organisation AbbVie Inc 
Sector Private
Country Global
Start 12/2013 
End 09/2015
 
Description BIOFLARE - Biological factors that limit sustained remission in Rheumatoid Arthritis
Amount £2,825,228 (GBP)
Funding ID MR/N026977/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 03/2019
 
Description BRC Clinical Training Fellowship
Amount £60,000 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description Bridging the third translational gap between industry and academia, creating a strong innovation culture at NU industry.
Amount £250,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2018 
End 09/2019
 
Description EMINEMT: Investigating Oncostatin M as a Mediator of Seronegative Inflammatory Arthritis
Amount £127,200 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 10/2019
 
Description EU IMI2 (Rheuma Tolerance for Cure [RTCure]) - KCL
Amount € 6,000,000 (EUR)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Multiple
Country European Union (EU)
Start 06/2017 
End 05/2022
 
Description EU IMI2 (Rheuma Tolerance for Cure [RTCure]) - Newcastle
Amount € 6,000,000 (EUR)
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Multiple
Country European Union (EU)
Start 06/2017 
End 05/2022
 
Description Immune-mediated inflammatory disease biobanks in the UK - IMIDBio_UK
Amount £218,084 (GBP)
Funding ID MR/R014191/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2017 
End 09/2020
 
Description Investigation into serum interferon-a as a prognostic marker of clinical response in early RA
Amount £15,143 (GBP)
Organisation British Society for Rheumatology (BSR) 
Sector Learned Society
Country United Kingdom
Start 09/2018 
End 08/2019
 
Description Investigation into serum interferon-a as a prognostic marker of clinical response in early RA
Amount £15,100 (GBP)
Organisation British Society for Rheumatology (BSR) 
Sector Learned Society
Country United Kingdom
Start 09/2018 
End 09/2019
 
Description Investigation of methotrexate metabolites in CD4+ T-Lymphocytes as a predictor of response to treatment in Rheumatoid Arthritis
Amount £263,289 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 09/2020
 
Description MATURA
Amount £550,614 (GBP)
Funding ID BH137922 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2014 
End 03/2018
 
Description MRC DiMeN DTP Studentiship: What fundamental dysregulation of the immune system underpins the development of rheumatoid arthritis?
Amount £76,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 09/2018 
End 09/2019
 
Description NIHR Newcastle Biomedical Research Centre in Ageing and Long-term conditions
Amount £17,460,811 (GBP)
Organisation National Institute for Health Research 
Department NIHR Biomedical Research Centre
Sector Academic/University
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description NIHR Translational Research Partnership
Amount £159,422 (GBP)
Funding ID BH122579 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 09/2012 
End 09/2018
 
Description Proximity to Discovery
Amount £250,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 07/2015 
End 12/2016
 
Description The Rheumatoid Arthritis Muscle Study RAMUS: JAK inhibition and rheumatoid cachexia
Amount £255,650 (GBP)
Organisation Pfizer Ltd 
Sector Private
Country United Kingdom
Start 11/2018 
End 10/2020
 
Description Translation and Diagnostics - bridging the third translational gap
Amount £100,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 03/2017 
End 08/2018
 
Title RA-MAP Systems Model 
Description Network-based and cross-platform models of response to treatment in rheumatoid arthritis. 
Type Of Material Model of mechanisms or symptoms - human 
Year Produced 2018 
Provided To Others? No  
Impact Currently in development the model and data to be made available by 2020. 
URL https://research.ncl.ac.uk/ra-map/
 
Title The RA-MAP Immunological Toolkit 
Description This development of this suite of immune biomarkers - the toolkit - is the major objective of the RA-MAP Consortium. It will be developed from biological material derived at 3 monthly intervals from TACERA study participants. 
Type Of Material Biological samples 
Year Produced 2018 
Provided To Others? No  
Impact In progress. Ongoing collaborations to 1) validate MATURA methotrexate responders and 2) validate Newcastle interferon gene signature. 
URL https://research.ncl.ac.uk/ra-map/
 
Title Diversity analysis of flow cytometry data 
Description A novel method to measure diversity of immune cells in RA patients, which can be used to detect changes in the immune profiling over time and to categorise RA patients into a number of subgroups (eg remission / non-remission at 6 months) 
Type Of Material Data analysis technique 
Year Produced 2017 
Provided To Others? Yes  
Impact None yet. 
 
Title FEMERA: Functional Endotyping Model for Early RA 
Description Projection of multi-dimensional data onto two dimensions for consistency scoring and identification of TNF-reactive and Lymphocytic RA endotypes. 
Type Of Material Computer model/algorithm 
Year Produced 2017 
Provided To Others? Yes  
Impact Application of a method developed by SimOmics permitting identification of endotypes in RA and mapping them to a systems model of RA. 
 
Title IMID-BIO UK Database 
Description Cross-consortia collaboration bringing together databases across the immune-mediated inflammatory diseases. 
Type Of Material Database/Collection of data 
Year Produced 2019 
Provided To Others? No  
Impact Validation of MATURA methotrexate responder signature. Validation of Newcastle interferon gene signature. 
URL https://gtr.ukri.org/projects?ref=MR%2FR014191%2F1
 
Title MedSciNet EDC for TACERA study 
Description A study specific Electronic Data Capture (EDC) system has been designed for the TACRA study. This will be the electronic Case Record Form (eCRF) for the study as well as forming part of the Study Management system. The system will also automatically enrol patients once they have been deemed eligible. The EDC system is designed to follow the order of the study assessments and include all the clinical data (incl. Medication history, lifestyle factors questionnaire, DAS28 etc). 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact The clinical dataset will be archived after the TACERA study closure and data will be available to other researchers upon request. 
 
Title PRE-RA: Predictors of Remission in Early RA. 
Description A cross-platform multi-omics model of predictors of remission for stratification of early RA patients. 
Type Of Material Computer model/algorithm 
Year Produced 2017 
Provided To Others? Yes  
Impact In preparation. 
 
Title RA-MAP Predictors of Remission 
Description We have amalgamated 19 datasets provided by the pharmaceutical industry into a single dataset. This required understanding and harmonisation of variables as well as re-anonymisation of the individual components of the dataset. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? No  
Impact The datasets will be provided to the MRC Biostatistics Unit at Cambridge. They are now working on identification of predictors of remission or a remission trajectory. Draft paper to be submitted Q2 2017. Second paper on transcriptomics data to be submitted Q2 2017. Multi-omics and additional papers in preparation for publication 2017-2018. 
 
Title RA-MAP-UNIVERSE 
Description The GitHub repository for the RA-MAP project. ALL data and code permitting prediction of remission in early arthritis patients to be made available to the wider research community. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact TBD 
URL https://github.com/RA-MAP-UNIVERSE
 
Title TranSMART RA-MAP Multiomics database. 
Description The Innovative Medicines Initiative eTRIKS team have provided technical support to the RA-MAP informatics team (Mike Barnes lead) to assist in the deployment of an open source datamart (TranSMART) for the RA-MAP projects. The TranSMART provides a useful repository tool for important data (patient clinical data, transcriptomics, metabolomics etc) that are acquired from the RA-MAP projects. The RA-MAP TranSMART is now operational and enabling secure data sharing between consortium members. 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact The Barnes team have propagated the support provided for RA-MAP to enable the deployment of additional TranSMART datamarts for the MRC-PSORT and MRC-MATURA projects. This has created a unique, common datamarts infrastructure across three closely related MRC projects investigating immune-inflammatory disease, creating opportunities for future data integration ad integrated analysis for stratified medicine and drug discovery. [Updates from March 2016] We are sharing curated public data in the database with the MRC-MATURA, MRC-PSORT and IMI-etriks projects Knowledge sharing and troubleshooting between these projects has enabled more rapid data curation and data infrastructure development for the project. We have also provided advice and troubleshooting on TranSMART configuration to the MRC-CHART (Juvenile Idiopathic Arthritis) and MRC-Masterplan (SLE) consortia [Updates from March 2017] As a complex, highly curated dataset, the RA-Map TranSMART is serving as an exemplar for development of TranSMART for the the MRC-MATURA, MRC-PSORT and MRC-MASTERPLANS projects. The project is also being used as a successful exemplar for multiple MRC stratified medicine applications. 
 
Description ARUK Centre of Excellence in rheumatoid arthritis pathogenesis 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years
Collaborator Contribution Each centre will provide a unique scientific contribution to the Centre
Impact Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University
Start Year 2013
 
Description ARUK Centre of Excellence in rheumatoid arthritis pathogenesis 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years
Collaborator Contribution Each centre will provide a unique scientific contribution to the Centre
Impact Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University
Start Year 2013
 
Description ARUK Centre of Excellence in rheumatoid arthritis pathogenesis 
Organisation University of Oxford
Department Kennedy Institute of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution WE have written a successful funding application to Arthritis Research UK for a Centre of Excellence in RA pathogenesis, value £2.5m over five years
Collaborator Contribution Each centre will provide a unique scientific contribution to the Centre
Impact Research grant, valu £2.5m spread across the three centres. Renewed 2019 with addition of KIR, Oxford University
Start Year 2013
 
Description ARUK-NIHR Newcastle Experimental Arthritis Treatment Centre 2016 
Organisation Versus Arthritis
PI Contribution Clinical, imaging, statistical and bioinformatics support.
Collaborator Contribution Infrastructure support including laboratory technical support, research nurses, project management, biostatistical and database management support. This has been crucial in tendering for other awards and trials.
Impact See Publications
Start Year 2012
 
Description ARUK/NIHR Musculoskeletal Experimental Medicine Conference, Nottingham, 2018 
Organisation NIHR CRN Staff and Facilities Throughout the UK
Country United Kingdom 
Sector Public 
PI Contribution Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology. Useful networking platform whose major function was to identify potential bottlenecks across infrastructure, regulation and PPI.
Collaborator Contribution Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology.
Impact Versus Arthritis are making a financial contribution to the NIHR NOCRI TRC in Inflammatory and Joint Diseases
Start Year 2018
 
Description ARUK/NIHR Musculoskeletal Experimental Medicine Conference, Nottingham, 2018 
Organisation Versus Arthritis
PI Contribution Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology. Useful networking platform whose major function was to identify potential bottlenecks across infrastructure, regulation and PPI.
Collaborator Contribution Contributor to discussions on the UK experimental and translational medicine landscape for rheumatology.
Impact Versus Arthritis are making a financial contribution to the NIHR NOCRI TRC in Inflammatory and Joint Diseases
Start Year 2018
 
Description COST consortium 
Organisation University of Warwick
Department Health Sciences Research Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution This is a new European network on tolerogenic cell therapies. The network is funded by COST (European Cooperation in Science and Technology) and is called 'Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies' (A FACTT). Co-applicant Hilkens was one of the initiators of this network, and she is leading the tolerogenic APC workgroup. The main objective of A FACTT is to coordinate European cell-based tolerogenic therapy efforts to minimise overlap and maximise comparison of the diverse approaches through establishment of consensus monitoring parameters. More information can be found on: http://www.afactt.eu/
Collaborator Contribution Co-applicant Hilkens was one of the initiators of this network, and she is leading the tolerogenic APC workgroup. The main objective of A FACTT is to coordinate European cell-based tolerogenic therapy efforts to minimise overlap and maximise comparison of the diverse approaches through establishment of consensus monitoring parameters.
Impact Several workshops have been held to date.
Start Year 2013
 
Description CRO Chiltern Programme 
Organisation Chiltern International
Country United Kingdom 
Sector Private 
PI Contribution n/a
Collaborator Contribution In 2013 Chiltern Activate was employed to facilitate TACERA study (early RA longitudinal study, a part of RA-MAP consortium) set up, which resulted in significant improvement of recruitment process. From 1st April 2014 the Clinical Monitoring team at Chiltern has been re-engaged to support recruitment at poorly performing sites.
Impact The RA-MAP consortium benefitted from this professional partnership by Chiltern's experience in facilitation of clinical study set up and recruitment processes.
Start Year 2013
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation Hospital de Madrid
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation Manchester University
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation NHS London
Country United Kingdom 
Sector Public 
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation Oslo University Hospital
Country Norway 
Sector Academic/University 
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation Reade
Country Netherlands 
Sector Hospitals 
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation Regional University Hospital of Tours
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation Sanquin
Country Netherlands 
Sector Charity/Non Profit 
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation St. George Hospital
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description EULAR Task Force on Therapeutic Monitoring of Biologics 
Organisation University of Amsterdam
Country Netherlands 
Sector Academic/University 
PI Contribution Chair the Study Group. Proposed EULAR Task Force with multiple academic and industry partners.
Collaborator Contribution TBD
Impact TBD
Start Year 2019
 
Description GSK 
Organisation Addenbrooke's Hospital
Department Addenbrooke's Centre for Clinical Investigation (ACCI)
Country United Kingdom 
Sector Hospitals 
PI Contribution Analysis of biomarkers
Collaborator Contribution Funding of clinical trial
Impact nil yet
Start Year 2009
 
Description IMI consortium RT-CURE 
Organisation Apitope
Country Belgium 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Johnson & Johnson
Country United States 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Karolinska Institute
Country Sweden 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Leibniz Association
Department German Rheumatism Research Centre
Country Germany 
Sector Charity/Non Profit 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Leiden University Medical Center
Department Department of Rheumatology
Country Netherlands 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Pfizer Inc
Country United States 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Royal Berkshire Hospital
Department Rheumatology Department
Country United Kingdom 
Sector Hospitals 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation Sanofi
Country Global 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation University Hospital Erlangen
Department Department of Rheumatology and Immunology
Country Germany 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation University of Bath
Department Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation University of Birmingham
Department Institute of Cancer and Genomic Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation University of Glasgow
Department Department of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMI consortium RT-CURE 
Organisation University of Queensland
Country Australia 
Sector Academic/University 
PI Contribution As a consequence of AuToDeCRA, we have been invited to partipicate in an EU-IMI proposal for tolerance-inducing therapies in rheumatic disease. Newcastle continues to contribute to the WP6 and related clinical WP6 work packages. AuToDeCRA 2 supported. Attendance at scientific meetings. Recommendations in development for regulatory discussion.
Collaborator Contribution Active contributions from all partners.
Impact The initial output will be a funding application. Monograph of Tolerising Therapies in preparation. Regulatory position statement in development.
Start Year 2015
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation King's College London
Department School of Biomedical Sciences KCL
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation Queen Mary University of London
Department School of Biological and Chemical Science QMUL
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation University of Cambridge
Department Cambridge-Africa
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation University of Glasgow
Department Mental Health Rights Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description IMID-BIO-UK Immune Mediated Inflammatory Diseases consortium 
Organisation University of Manchester
Department Mancester Breast Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution Contributed to strategic planning for the IMID-Bio-UK consortium and prospective grant awards.
Collaborator Contribution All partners manage individual consortia researching immune-mediated inflammatory diseases. All partners contributed to further funding applications.
Impact EU IMI 'Big Data' grant submission - unsuccessful. MRC 'Comorbidities' grant submission - second stage though unsuccessful.
Start Year 2018
 
Description Joint TRC-Janssen Collaboration 
Organisation Johnson & Johnson
Department Janssen Pharmaceuticals
Country United States 
Sector Private 
PI Contribution Designed and performed a specific experimental medicine research study.
Collaborator Contribution Designed and performed the study; analysed samples from the study.
Impact Plans for future collaboration.
Start Year 2016
 
Description King's Health Partners (Viapath) 
Organisation Viapath
Country United Kingdom 
Sector Private 
PI Contribution n/a
Collaborator Contribution Partnership with King's Health Partners (Viapath) to undertake assays for rheumatoid factor and anti-CCP antibodies, and high sensitivity CRP assays in serum from the first 300 patients recruited to the PREVeNT RA cohort of first degree relatives of patients with RA.
Impact None yet.
Start Year 2014
 
Description MATURA consortium 
Organisation Cardiff University
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation Queen Mary University of London
Department William Harvey Research Institute
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Hertfordshire
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MATURA consortium 
Organisation University of Sheffield
Country United Kingdom 
Sector Academic/University 
PI Contribution recruitment to the STRAP trial proteomic analyses
Collaborator Contribution The overarching mission of the MATURA Consortium is to improve patient care in rheumatoid arthritis (RA) by rationalising therapy decisions through the use of a stratified medicines approach. Background: RA provides the ideal setting for the introduction of a stratified medicine approach because, first, the treatment is standardised in England through National Institute of Health and Clinical Excellence (NICE) guidance such that methotrexate (MTX) is the first choice disease modifying anti-rheumatic drug (DMARD); patients who fail to respond to MTX and at least one other DMARD are eligible for biologic TNF pathway blocking drugs (anti- TNFs) or, more recently IL6 pathway blocking drugs, tocilizumab (TOC), and those who fail to respond to anti-TNF can then be switched to the biologic B-cell depleting therapy, rituximab (RTX). Second, it is well established that there is a significant non - response rate to each drug (MTX (45% by 2 years), anti-TNF (25% by 6 months) and RTX (40% by 6 months). Third, the biologic drugs (anti-TNF, TOC and RTX) are expensive and all 4 drugs are associated with serious adverse events; hence, identifying those patients least likely to respond would improve the cost-benefit analysis. Finally, introduction of early, effective therapy has consistently been shown to improve long-term outcomes including joint damage, disability and employment. Aim: To identify treatment response predictors which will allow the allocation of patients to strata defined by the therapy they are most likely to respond to, early in the disease process. Methods: Two parallel workstrands (WS) will investigate synovial tissue (WS.1) and peripheral blood (WS.2) to identify biomarkers of response. Thus, in WS.1 we shall search for tissue-driven biomarkers and blood correlates in the largest synovial tissue biobank of this type (2 time points 0 & 6 months biopsy) in the world & clinical datasets (over 200 patients immediately available). In addition, in a prospective randomised clinical trial (adaptive design) we will test the hypothesis that discrete cellular and molecular signatures in the synovial tissue ("pathotypes") will enrich for response to existing biologic therapies. In WS.2, we will take advantage of the large observational cohorts of patient samples either already collected or which could be collected for minimal cost to undertake a comprehensive analysis to identify genetic, genomic, transcriptomic, proteomic or, more likely, a combination of these factors that will reliably identify responders/non-responders to each of the drugs. These collections include biological samples from over 3,000 anti-TNF-, 1,500 MTX-, 1,200 RTX- and 200 TOC-treated subjects. The two WSs are fully integrated through "multi-omic" approaches that constitute cross-cutting themes (CTs) that will converge in a large analytical and modelling package driven by experts in Bioinformatics and Statistics and allow preliminary health economic assessments of identified biomarkers. Finally, in collaboration with our Industry partners we have drawn up plans to commercialize potential diagnostics for patient benefit and wealth generation. Outcome: By the end of the study, we will have identified biomarkers of response for four of the most commonly used drugs in the treatment of RA. The study design allows a comprehensive and cohesive assault on the problem of identifying, which patients will respond best to which treatments in RA and has the potential for enormous clinical and economic impact.
Impact Medicine statistics bioinformatics multiple industry partners
Start Year 2014
 
Description MRC ABPI RA MAP Project 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution I am the UK Chief Investigator on the PREVeNT RA work stream in this MRC ABPI Award
Collaborator Contribution There are 6 core centres involved in this collaboration and in Manchester we lead on several of the Epidemiology Projects
Impact Studies are underway and early papers to follow
Start Year 2011
 
Description MRC ABPI RA MAP Project 
Organisation Newcastle University
Country United Kingdom 
Sector Academic/University 
PI Contribution I am the UK Chief Investigator on the PREVeNT RA work stream in this MRC ABPI Award
Collaborator Contribution There are 6 core centres involved in this collaboration and in Manchester we lead on several of the Epidemiology Projects
Impact Studies are underway and early papers to follow
Start Year 2011
 
Description Partnership between University of Birmingham and Protagen 
Organisation Protagen AG
Country Germany 
Sector Private 
PI Contribution Partnership between UoB and Protagen to look at autoantibody profiles in arthritis associated with anti-PD1 therapy. This arose in part through contacts made at RA-MAP. Transfer of samples governed by MTA.
Collaborator Contribution Partnership between UoB and Protagen to look at autoantibody profiles in arthritis associated with anti-PD1 therapy. This arose in part through contacts made at RA-MAP. Transfer of samples governed by MTA.
Impact None yet (autoantibody profiling in arthritis patients associated with anti-PD1 therapy)
Start Year 2016
 
Description Protagen joins as a new RA-MAP partner 
Organisation Protagen AG
Country Germany 
Sector Private 
PI Contribution Serum samples from early RA cohort (TACERA study, n=275) together with healthy controls (from Vaccine Study, n=50) will be provided to Protagen for autoantibody profiling by Protagen's SeroTag® platform.
Collaborator Contribution Protagen has examined autoantibodies to over 7,000 human proteins in the serum samples provided by the RA-MAP consortium. Protagen AG provided the technological platform, ran the analytical lab work, the statistical analysis and covered its own operational costs.
Impact None yet.
Start Year 2015
 
Description RA-MAP Consortium 
Organisation Abbott
Department Abbott UK
Country United Kingdom 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation Amgen Inc
Country United States 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation Bristol-Myers Squibb
Country United States 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation European Translational Information and Knowledge Management Services (eTRIKS)
Country European Union (EU) 
Sector Charity/Non Profit 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation F. Hoffmann-La Roche AG
Country Global 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation Johnson & Johnson
Department Janssen Pharmaceuticals
Country United States 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation MedImmune
Country United States 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation Queen Mary University of London
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation UCB Pharma
Country United Kingdom 
Sector Private 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University of Birmingham
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University of Cambridge
Department MRC Biostatistics Unit
Country United Kingdom 
Sector Public 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University of Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University of Leeds
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University of Manchester
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description RA-MAP Consortium 
Organisation University of Oxford
Department Kennedy Institute of Rheumatology
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration is led and coordinated by Newcastle University. There are 2 Work Packages. Newcastle University lead and contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples. Newcastle University contribute to WP1, by recruiting early RA patients to the TACERA study. To eTRIKs the provision of clinically curated "omics" datasets to drive the development of a common KM platform to store data and allow the comparative analysis of clinical data
Collaborator Contribution 7 Academic partners contribute to WP2, "the development of an immunological toolkit" which is based on the development of assays and the identification of biomarkers from early RA clinical samples and will also contribute to WP1, by recruiting early RA patients to the TACERA study. * MRC Biostatistics Unit have provided SAPs for each of the studies *KCL lead the TACERA study *Glasgow lead the Vaccine Substudy on healthy vaccinees *Manchester lead PREVEnTRA to establish a cohort of First Degree Relatives of RA patients *Manchester University lead and coordinate the collation of RCT patient level data to identify Predictors of Remission. *Industry partners provide "in kind" support for 1. Study Operations and Coordination 2. Bioinformatics, statistics and data analysis expertise 3. Data analysis platforms and knowledge management In particular a Consortium of industrial partners (eTRIKs) have provided secure data storage via access to a KM platform (Transmart). Expertise in Knowledge Management. Namely provision of specialist expertise i) to develop the database to accept data types from various technology platforms and ii) to link data storage to specific analysis software Expertise as In kind contributions from company partners has been valued at £111,082 with personnel rates based on full loaded costings. This amounts to ~12.7% of the value of the MRC grant awarded to cover project work in the first year.
Impact N/A Too early in project to report outputs
Start Year 2012
 
Description SOMAlogic (CRO) 
Organisation SomaLogic
Country United States 
Sector Private 
PI Contribution Plasma samples from RA-MAP TACERA study and Vaccine study were provided for SOMAscan proteomics analysis, The resulting data have been extensively analysed by the industry members of the RA-MAP consortium. The cost of the analysis has been covered by crowd sourcing amongst the RA-MAP industry partners (£90K).
Collaborator Contribution Provision of SOMAscan proteomics analysis of TACERA baseline and 6 month plasma samples, and healthy control samples from the vaccine study.
Impact RA disease stratification of TACERA patients.
Start Year 2016
 
Description SimOmics Ltd 
Organisation Simomics Ltd
Country United Kingdom 
Sector Private 
PI Contribution Provision of RA-MAP omics dataset for systems immunology collaborative project
Collaborator Contribution SimOmics has been working closely with the team of systems immunologists in the RA-MAP consortium since Q1 2016. They contribute with systems analysis of RA-MAP RA omics database and metabolic flux analysis.
Impact None yet
Start Year 2016
 
Description Tepnel Pharma Services 
Organisation Tepnel Pharma Services
Country United Kingdom 
Sector Private 
PI Contribution Providing biological materials arising from TACERA clinical study cohort for RNA processing
Collaborator Contribution RNA processing and miicroarray services for samples deried from TACERA clinical study
Impact Tepnel has taken up the role of RNA processing and RNA microarray which feeds directly into Transcriptomics package of RA-MAP.
Start Year 2015
 
Description WTCHG for NGS 
Organisation University of Oxford
Department Oxford Genomics Centre
Country United Kingdom 
Sector Academic/University 
PI Contribution RA-MAP has provided RNA samples from TACERA clinical study cohort.
Collaborator Contribution Oxford Genomics has provided next generation sequencing of TACERA study RNA materials.
Impact Oxford Genomics has provided expertise in generating NGS data for RA-MAP consortium.
Start Year 2015
 
Description 'Behind the scenes' - open evening event at the Manchester Royal Infirmary rheumatology department 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Patients, carers and/or patient groups
Results and Impact "Behind the scenes" - open evening event was held at the Manchester Royal Infirmary rheumatology department, May 2015. Patients and carers were invited to meet staff and discuss research options - talks, examples of how research is conducted, opportunity to speak to research staff
Year(s) Of Engagement Activity 2015
 
Description 'Platform for Investigation' Event at Manchester Muserum of Science and Industry 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Manchester researchers were involved in awareness-raising activities at the Manchester Museum of Science and Industry held in April 2015. One day event with 800+ visitors, mainly families with children.
Year(s) Of Engagement Activity 2015
URL http://www.cmft.nhs.uk/media-centre/latest-news/explore-joints-and-genes-at-the-museum-of-science-an...
 
Description 9th International Symposium on Uveitis Dublin 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lecture on Biologics in Rheumatology
Year(s) Of Engagement Activity 2016
 
Description ACR 2016 Abstract Selection Panel 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Co-chair of RA-aetiology and RA-pathogenesis categories. Reviewed 15 abstracts, selected those for presentation and ordered the session.
Year(s) Of Engagement Activity 2016
 
Description ACR 2016 Washington 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote address on 'Biologic Agents'
Year(s) Of Engagement Activity 2016
 
Description ARUK Arthritis Matters 2014 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact There was useful discussion after my presentation about the reach of charitable funding

Patients volunteered to join TRAFIC steering group
Year(s) Of Engagement Activity 2014
URL http://www.musculoskeletalresearch.com/2014/07/arthritis-matters-2014.html
 
Description ARUK Strategy Meeting Newcastle 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Strategy discussion with Liam O'Toole and Steve Simpson
Year(s) Of Engagement Activity 2016
 
Description ARUK T-reg Workshop, London, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Supporters
Results and Impact A workshop that involved several charities and international experts. The goal to promote collaborative research and funding around the role of Tregs in autoimmune diseases.
Year(s) Of Engagement Activity 2018
 
Description ARUK/CRUK Joint Planning Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Joint planning meeting for symposium embracing common interests eg. checkpoint inhibitors.
Year(s) Of Engagement Activity 2016
 
Description ASPIRE 2016 Research Awards 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Pfizer rheumatology research awards.
Year(s) Of Engagement Activity 2016
URL http://www.aspireresearch.org/Rheumatology/index.html
 
Description Adherence Workshop - Manchester 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Organized by my ARUK CSG - workshop on treatment adherence.
Year(s) Of Engagement Activity 2016
 
Description American College of Rheumatology (November 2015, California) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact PREVeNT RA Serum Biomarkers abstract was an abstract for a talk given by Prof Bruce at the ACR (American College of Rheumatology) November 2015
Year(s) Of Engagement Activity 2015
 
Description An Embrassment of Riches 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact 100 individuals attended a session at BSR which I had organised, highlighting the importance of engaging patients in research

This activity should improve recruitment to clinical trials, particularly from non-academic centres
Year(s) Of Engagement Activity 2013
 
Description Antigen-Specific Immune Tolerance Europe, London, 2018 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presented on RA-MAP and the TRC as examples of acadaemia-industry collaboration. Useful industry contacts on peptide therapeutics, CAR T-cells and other biotechnologies.
Year(s) Of Engagement Activity 2018
URL https://www.as-immunetolerance-eu.com/
 
Description BSR 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Best practice in rheumatology research.
Year(s) Of Engagement Activity 2016
URL http://www.rheumatology.org.uk/
 
Description BSR 2016 Abstracts 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Reviewed 26 BSR Abstracts
Year(s) Of Engagement Activity 2016
 
Description BSR 2016 Glasgow Signalling Pathways 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Chaired the Pfizer session on Signalling Pathways
Year(s) Of Engagement Activity 2016
 
Description BSR Manipulating The Immune System - Birmingham 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact This was a lecture to rheumatologists in training on novel immunologically based therapies, at the annual BSR AGM.
Year(s) Of Engagement Activity 2017
URL https://www.eiseverywhere.com/ehome/rheumatology2017/423982/
 
Description BT-CURE Workshop - Stockholm 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact AuToDeCRA Lecture and RT-CURE IMI proposal
Year(s) Of Engagement Activity 2016
 
Description BT-CURE workshop May 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact This was a workshop of an existing EU-FP& consortium, which is now developing an IMI application for tolerogenic therapies in RA. I was invited to participate as a member of the proposed IMI academic/industry consortium
Year(s) Of Engagement Activity 2016
 
Description Biomedical Research Unit Open Day (Manchester) - Disease Prevention 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact The Biomedical Research Unit (Musculoskeletal) in Manchester held its annual open day in May 2014, with this year's theme being on disease prevention. The open day provided staff from the regional institutions, hospitals and members of public to learn more about the research being carried out into disease prevention. This included a presentation given by Professor Ian Bruce on the PREVeNT RA study, introducing the study focussed on prevention of rheumatoid arthritis.

Increased public awareness of currently on-going studies aimed at disease prevention, in particular rheumatoid arthritis.
Year(s) Of Engagement Activity 2014
 
Description CLUSTER Consortium - London, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact Strategic plans for MRC-funded stratified medicine programme in JIA and associated Uveitis. JDI chairs the external SAB.
Year(s) Of Engagement Activity 2018
URL https://juvenilearthritisnews.com/2018/04/02/cluster-consortium-aims-improve-jia-uveitis-patients-li...
 
Description Cafe Scientifique (PREVeNT RA), Cockermouth, Cumbria 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Professor Ian Bruce (PI for the PREVeNT RA study) gave a presentation of arthritis, based on his research. It provoked significant discussion about how lifestyle may influence arthritis development.
Year(s) Of Engagement Activity 2015
 
Description Cafe Scientifique (PREVeNT RA), Pendle, Lancashire 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Professor Ian Bruce (PI for the PREVeNT RA study) gave a presentation of arthritis, based on his research. It provoked significant discussion about how lifestyle may influence arthritis development.

Professor Bruce has been invited to give a further talk and the group sent a recording of his talk to other similar groups in England to raise awareness.
Year(s) Of Engagement Activity 2014
 
Description Central & Eastern European Immunology Forum Bucharest 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact New Treatments for Immune Mediated Inflammatory Diseases
Year(s) Of Engagement Activity 2016
 
Description Clinical Decision Making - Statistics and Health Economics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Latent variable methods for clinical decision tools.
Year(s) Of Engagement Activity 2017
 
Description Conservative Muslim Forum (London) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Professor Ian Bruce presented a talk to explore the question "Precision Medicine : An Achievable Goal?"
He discussed how precisely can diseases be treated in a way that is specific to the individual patient. He gave an in depth analysis of research in Rheumatology and the fact that there are 8 million people affected by the disease. Despite the complexity of the subject, Professor Bruce managed to make it accessible to the layman.
Professor Bruce alos talked about how research in the UK is fundedm and gave a breakdown of the various research being done by Medical Research Council and the National Institute of Health Research. Whilst the NHS's total budget is over £100 billion, the share devoted to research is under 3%.
For most people, the most fascinating part of the evening was listening to Professor Bruce on the general theme of medication. He he talked about medicine being "partly art, partly science." Most drugs prescribing is on a trial and error / best guess basis, using the likely benefit to the average person. He talked about "personalised medicine" which would target the medicine to the individual patient, and "stratified medicine" which groups patients into categories to assess which medicine to use, being intermediate between using data for the average person and data for the specific individual.
Year(s) Of Engagement Activity 2015
URL http://www.conservativemuslimforum.com/news~events/news-&-past-events/health-event-precision-medicin...
 
Description DMC MATCH Macrophage Study Newcastle 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Study of macrophage therapy in liver cirrhosis.
Year(s) Of Engagement Activity 2016
 
Description DRFZ Scientific Advisory Board Meeting Berlin 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact DRFZ is Germany's premier Rheumatology Institute - Radbruch
Year(s) Of Engagement Activity 2016
 
Description Drug Discovery Catapult - Alderley Park 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact Discussions with the Medicines Discovery Catapult around access by SMEs to RA-MAP biobanked samples.
Year(s) Of Engagement Activity 2017
URL https://md.catapult.org.uk/
 
Description EMEUNET Meeting Lisbon 2016 Immune Tolerance - Where Next? 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Immune Tolerance: RA - Where Next?
Year(s) Of Engagement Activity 2016
 
Description EMINENT GSK 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact To discuss a new funding stream from GSK and MRC for collaborative, experimental medicine research
Year(s) Of Engagement Activity 2015
 
Description EULAR 2015 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Prospective collaboration with Pfizer
Year(s) Of Engagement Activity 2015
 
Description EULAR 2016 London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chaired the satellite symposium on Biosimilars - Kweim, Dorner - presentation on Refractory RA
Year(s) Of Engagement Activity 2016
 
Description EULAR 2019 Organizing Committee 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Preparing for EULAR 2019 (Madrid). JDI is Abstracts Chair, a majpr role in the organising committee..
Year(s) Of Engagement Activity 2018,2019
URL https://www.congress.eular.org
 
Description EULAR Research Centre, London, 2019 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Strategic discussions around a prospective, collaborative, virtual research centre for European Rheumatic and Musculoskeletal Disorders groups.
Year(s) Of Engagement Activity 2019
 
Description EULAR Scientific Programme Committee 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Planning meeting for EULAR 2019 in Madrid. As Abstract Chair I play a major role in this meeting.
Year(s) Of Engagement Activity 2018
URL http://congress.eular.org/index.cfm
 
Description EULAR Therapeutic Drug Monitoring Study Group, Amsterdam, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chaired this EULAR Study Group reviewing therapeutic drug monitoring. Decision taken to apply for EULAR Task Force status in 2019.
Year(s) Of Engagement Activity 2018
URL https://www.eular.org/clinical_affairs_study_groups.cfm
 
Description Efficient Medical Technology Development 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Facilitated workshop mapping roadblocks to the development pathway for new technologies.
Year(s) Of Engagement Activity 2017
 
Description European Workshop for Rheumatology Research, Lyon, 2019 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Annual research workshop, provides the opportunity for postgrad students and ECRs to present their work to an international audience. One of our students had an oral presentation and another presented a poster.
Year(s) Of Engagement Activity 2019
URL http://www.ewrr.org/
 
Description GSK Industry Engagement Visit Newcastle 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Explored shared interests - potential for interaction - biopsy procedures
Year(s) Of Engagement Activity 2016
 
Description Genesis Conference (London) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Dr Mike Barnes presented a talk entitled: Technologies empowering Omics in the sessioin "Empowering Technologies"
Year(s) Of Engagement Activity 2015
URL http://www.cambridgeahead.co.uk/2015/12/genesis-2015-london-10th-december/
 
Description Genomics Research in the NE Quadrant - York 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Participation in meeting on the future of genomics research in the NE Quadrant, as a component of NHS England's reorganisation of clinical genetics services.
Year(s) Of Engagement Activity 2018
 
Description Great North Experimental Arthritis Treatment Centre website 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Participants in your research and patient groups
Results and Impact The activity is ongoing
Year(s) Of Engagement Activity 2014
URL http://www.greatneatcentre.com/
 
Description IMID-BIO Cambridge, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Annual scientific and strategic planning meeting for IMID-BIO UK.
Year(s) Of Engagement Activity 2018
URL https://www.arthritisresearchuk.org/research/news-for-researchers/2017/december/our-role-in-the-worl...
 
Description IMID-BIO Science Day - Glasgow 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Scientific meeting of the IMID-BIO project, which brings together several stratified medicine consortia.
Year(s) Of Engagement Activity 2018
 
Description Immune mediated Inflammatory Diseases Workshop: Wellcome Trust 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This 2 day workshop brought together a wide spectrum of experts across immune mediated diseases to discuss challenges and future opportunities to learn more about immune mediated conditions. Several potential collaborations were discussed
Year(s) Of Engagement Activity 2017
 
Description Immunogenicity Research Forum 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Prospective collaborations
Year(s) Of Engagement Activity 2015
 
Description International Forum for RA 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact The International Forum for RA is a meeting focussed on cutting edge research in rheumatoid arthritis, with an emphasis on influencing future management strategies. I gave a presentation around 'smart trial designs'. This led to a new collaboration with Dana Orange (Rockefeller).
Year(s) Of Engagement Activity 2017
 
Description International Psoriasis Council Symposium, Munich September 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact I spoke on P4 medicine in rheumatology and how such an approach can better address patient stratification
Year(s) Of Engagement Activity 2016
 
Description Inventory of Trials Study Workshop on Predictors of Remission Study 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Workshop for the Predictors of Remission study was organised in Manchester by Prof Jane Worthington, Prof Deborah Symmons, Prof Ian Bruce and Ms Fiona Stirling. The workshop provided an opportunity to feed back information and analyses of the pooled clinical datasets from the 7 consortium member organisations. The meeting was successful, supported by approximately 20 participants contributing from these organisations (mixture of academic and industry partners).

The findings of the study are planned to be incorporated into a manuscript under preparation by Prof Deborah Symmons. This workshop also promoted further data to be produced in order to strengthen the powering of the results. In addition, Brian Tom (study statistician for the RA-MAP consortium) was invited to speak at PSI (Statisticians in the Pharmaceutical Industry) conference in May 2015.
Year(s) Of Engagement Activity 2014
 
Description JDRF Workshop - Common Mechanisms of Autoimmune Conditions 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prospective collaborations
Year(s) Of Engagement Activity 2015
 
Description Janssen Disease Area Stronghold Scientific Symposium Newark 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Featuring imaging presentations.
Year(s) Of Engagement Activity 2016
 
Description Launch of the Medicines Discovery Catapult (January 2017, Alderley Park) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact The Catapult is an important partner for our BRC and this launch event introduced us to new collaborators and potential funding streams
Year(s) Of Engagement Activity 2018
 
Description Lecture on "Stratified approaches to the treatment of rheumatoid arthritis" (Newcastle University MSc in Genomic Medicine) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Postgraduate students
Results and Impact Newcastle PI John Isaacs gave a lecture on stratified medicine in RA to the Genomics Medicine MSc at Newcastle University. This was provided to medical students who all work full time in the NHS.
Year(s) Of Engagement Activity 2016
 
Description MATURA Scientific Symposium - Manchester 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Scientific meeting bringing together the findings of the MATURA trial. Newcastle presented data on our proteomics analysis.
Year(s) Of Engagement Activity 2017
URL http://www.matura.whri.qmul.ac.uk/what_is_matura.php
 
Description MATURA Workshop 2017 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentations by ES and CMB
Year(s) Of Engagement Activity 2017
 
Description MRC DPFS Meeting - London 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The DPFS scheme is a key part of the MRC's Translational Research Strategy and supports the translation of fundamental discoveries toward benefits to human health. It funds the pre-clinical development and early clinical testing of novel therapeutics, devices and diagnostics, including "repurposing" of existing therapies.
Remit
The scheme supports academically led projects whose goals are to improve prevention, diagnosis, prognosis, or treatment of significant health needs, or that focus on developing research tools that increase the efficiency of developing interventions.
Year(s) Of Engagement Activity 2018
URL https://www.mrc.ac.uk/funding/browse/biomedical-catalyst-dpfs/biomedical-catalyst-developmental-path...
 
Description MRC DPFS Panel Meeting - London 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Reviewed seven outline applications and two full applications for MRC Development Pathway Funding Scheme.
Year(s) Of Engagement Activity 2016
 
Description MRC Newcastle University Visit 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Review and round table discussions of Newcastle University research outputs and statistics.
Year(s) Of Engagement Activity 2018
 
Description MRC Platforms Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Dr Michael Barnes presented a talk entitled "Platforms for Data integration"
Year(s) Of Engagement Activity 2015
 
Description MRC RA-MAP CMB and PSG Meetings London 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Strategic planning around future research directed at predictors of remission in RA.
Year(s) Of Engagement Activity 2016
 
Description MRC Research Strategy Visit 2016 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Reviewed medical research at Newcastle highlighting achievements in experimental medicine and translational research and identifying improvement opportunities.
Year(s) Of Engagement Activity 2016
 
Description MRC Stratified Medicine Consortia in Immune-Inflammatory Diseases Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact This workshop explored common characteristics across a number of key consortia and has helped to better understand common challenges in the mechanisms of these conditions as well as common methodological challenges
Year(s) Of Engagement Activity 2016
 
Description MRC Stratified Medicine Initiative - Strategy Workshop 2013 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact MRC Stratified Medicine Strategy Workshop
4th July 2013
London
Science of Strat Med Consortia -

Assisted the broader community in better understanding the opportunities and challenges posed by taking a stratified medicine approach
Year(s) Of Engagement Activity 2013
 
Description MRC Stratified Medicine, London, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Review of progress for the MRC Stratified Medicine Consortia and Pathology Nodes.
Year(s) Of Engagement Activity 2018
 
Description MRC TRG Meeting - London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The MRC Translational Research Group (TRG) is responsible for ensuring strong continued support for translational research across the MRC. It supports translational research across MRC funding Boards and Panels, through partnerships with other funders and major Higher Education Institutions and through dedicated funding schemes. Areas of particular focus for TRG include:
The Biomedical Catalyst, an integrated translational funding programme jointly operated with Innovate UK (formerly the Technology Strategy Board).
The Confidence in Concept scheme, supporting academically led feasibility research at the institutional level.
The Developmental Pathway Funding Scheme, part of the Biomedical Catalyst, supporting translation of fundamental discoveries toward benefits to human health.
The Methodology Research Programme, in partnership with the National Institute for Health Research (NIHR).
Coordination with the MRC-NIHR Efficacy and Mechanism Evaluation Programme (EME) programme and other NIHR funding schemes to ensure suitable projects progress to late-stage trials.
Year(s) Of Engagement Activity 2017
URL https://www.mrc.ac.uk/about/our-structure/strategy-board-overview-groups/translational-research-grou...
 
Description MRC Technology Strategy Board Stratified Medicine Showcase 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact MRC Technology Strategy Board Stratified Medicine Showcase
30th Oct 2013
London
Delivering the Impact

To be reported
Year(s) Of Engagement Activity 2013
 
Description MRC Translational Research Group 2016 Strategy Meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Developing translational research strategy for the UK
Year(s) Of Engagement Activity 2016
 
Description MRC/ABPI RA-MAP Final Meeting - London 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Sharing the research results of the RA-MAP project.
Year(s) Of Engagement Activity 2017
 
Description MRCstratified medicine workshop April 2014 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Audience of approximately 20 PIs plus MRC staff - a view from the expert panel

Enhanced recognition for Newcastle as a centre for translational medicine
Year(s) Of Engagement Activity 2014
 
Description MSc Genomics Newcastle 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Postgraduate students
Results and Impact Stratified Medicine in RA
Year(s) Of Engagement Activity 2016
 
Description Methodology for Stratified Medicine 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prospective collaborations
Year(s) Of Engagement Activity 2015
 
Description NE Inflammation Forum - Newcastle 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact Pfizer chair - Coady, Goff, Sheikh, Taylor, Thompson.
Year(s) Of Engagement Activity 2016
 
Description NHSA Meeting ( September 2017, Newcastle) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact NHSA meeting to plan collaborative work across the Northern BRCs
Year(s) Of Engagement Activity 2017
 
Description NICE Diagnostic Advisory Committe, Manchester, 2019 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Development of draft recommendations on Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis. These will be published for public consultation before formal recommendations are published.
Year(s) Of Engagement Activity 2019
 
Description NIHR BRC Impact Showcase, Newcastle, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Showcase event attended by senior figures from the Department of Health and major charities including Versus Arthritis. The CEOs of the Trust and University attended. Musculoskeletal presentations included patient presentations and videos. Ken Baker was awarded a prize for best oral presentation. Sir John Burn and Dame Jackie Daniel presented their vision for Newcastle.
Year(s) Of Engagement Activity 2018
URL https://www.newcastlebrc.nihr.ac.uk/events/nihr-newcastle-biomedical-research-centre-impact-showcase...
 
Description NIHR TRP Committee Meeting 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact TRP strategic meeting.
Year(s) Of Engagement Activity 2016
 
Description NIHR TRP Pipeline Meeting - London 2016 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Discussed pipeline and promotion of early stage trials - limitations of PIC sites - BRC roles
Year(s) Of Engagement Activity 2016
 
Description NOVARTIS Biomedical Research Foundation (June 2017, Mayfair) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A meeting between NIHR and Novartis to discuss potential engagement of Novartis in the UK
Year(s) Of Engagement Activity 2017
 
Description NRAS magazine article 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Type Of Presentation Paper Presentation
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Article on the importance of adherence to therapy for NRAS magazine

This magazine has a wide circulation amongst patients with RA and is also available on-line
Year(s) Of Engagement Activity 2014
 
Description Non-Pharmacological Interventions Workshop ARUK AIA CSG 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prospective collaborations
Year(s) Of Engagement Activity 2015
 
Description Open Innovation in the NHS workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact On the 2nd April 2014 the Academy of Medical Sciences hosted a workshop in partnership with the Centre for the Advancement of Sustainable Medical Innovation (CASMI) to bring together members of academia, industry, the NHS, funding bodies and IP experts. The discussion focused on the key issues and opportunities surrounding collaboration with the NHS, focusing particularly on 'open innovation' models of partnership. Professor Andrew Cope (PI of RA-MAP study) contributed by presenting the MRC/ABPI-funded RA-MAP consortium as an exemplar of open innovation in the NHS and model of academia-NHS-industry collaboration.

Delegates enjoyed four case presentations that highlighted the advantages of open collaboration models and also some of the barriers and frustration involved with these partnerships. Following a candid and constructive period of discussion, delegates highlighted four areas that they considered to be the most significant barriers to open innovation. These were: lack of metrics, poor incentivisation and reward for innovation, cultural conflicts between sectors and poor use of existing structures. Delegates then worked in groups to consider novel solutions to overcoming these barriers and facilitate open innovation partnerships with the NHS.
Year(s) Of Engagement Activity 2014
URL http://www.acmedsci.ac.uk/policy/policy-projects/open-innovation-in-the-nhs/
 
Description Personalized Medicine - Brazil 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Lecture tour presenting four talks on Personalized Medicine at three research centres in Brazil.
Year(s) Of Engagement Activity 2016
 
Description Pfizer 2016 Berlin Meeting to develop educational materials around Tofactinib treatment. 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Meeting to develop educational materials to support Tofactinib treatment sponsored by Pfizer.
Year(s) Of Engagement Activity 2016
 
Description Pfizer EARTH Ad Board - Paris 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Co-chaired the Ad Board
Year(s) Of Engagement Activity 2016
 
Description Pfizer JAK Inhibition Symposium 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talks and informal discussions on RA pathophysiology and potential novel treatments.
Year(s) Of Engagement Activity 2016
 
Description Portuguese Congress of Rheumatology 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Networking and strategic planning with international collaborators.
Year(s) Of Engagement Activity 2016
 
Description Portuguese Society of Rheumatology - Algarve 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Keynote Lecture - New Treatments for IMID - invited paper to Annals Review
Year(s) Of Engagement Activity 2016
 
Description Precision Medicine UK 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact NOCRI joined UK leaders in the research, development and commercialisation of precision medicine for a one-day event this week designed to encourage new partnerships and highlight new opportunities in the field.

The Precision Medicine UK: Collaboration Nation event at De Vere Holborn Bars, London, on 9 December was organised on behalf of the Stratified Medicine Innovation Platform by Innovate UK,, National Institute for Health Research, Cancer Research UK,Medical Research Council, Invest Northern Ireland, Health and Care Research Wales and the Knowledge Transfer Network, with the NIHR Office for Clinical Research Infrastructure (NOCRI) coordinating the NIHR's involvement.

The day formed part of a programme to make the UK a world leader in precision medicine and provided real-world examples of the discovery and development of precision medicine solutions, through talks, panel discussions, workshops and exhibitions with the opportunity to arrange one-to-one partnering meetings.

Precision medicine is an emerging approach to the treatment and diagnosis of disease that takes into account variations in a patient's genes, environment and lifestyle. It aims to better target treatments to an individual's circumstances to improve outcomes for patients.

Representatives from across the NIHR were involved in the day and presented on a range of projects and funding programmes. Professor Bryan Williams of NIHR UCLH Biomedical Research Centre joined the first panel of the day which highlighted UK investments in the invention and evaluation phase of research. Professor Williams' highlighted key NIHR's investments in this space and provided examples of exciting precision medicine projects from UCLH BRC. In addition, a number of NIHR precision medicine projects were presented during the disease area specific showcase sessions. This included Professor Costantino Pitzalis who presented the THERAPIST study on behalf of the NIHR Translational Research Partnership, Professor Simon Mead's who presented a project at NIHR Queen's Square Biomedical Research Unit on the "dementia chip" and Professor Tariq Sadiq's who presented on Capacity Building and Delivery of Precision Medicine in Sexual Health, through NIHR Funding. Mark Samuels, Managing Director of NOCRI, also chaired a discussion panel themed 'Enabling Collaboration', which highlighted the value of collaborative working between companies, academics, charities and patients.

The event saw the launch by the chief executive of Innovate UK, Dr Ruth McKernan, of a new map of the precision medicine landscape.

A whole range of organisations, including charities, health bodies and devolved administrations are coordinating their work under the umbrella of Innovate UK's Stratified Medicine Innovation Platform, with NOCRI representing the NIHR.
Year(s) Of Engagement Activity 2015
URL http://www.uk-pgx-stratmed.co.uk/index.php/event-calendar/icalrepeat.detail/2015/12/09/213/73/-
 
Description Presentation to Industrial partners at American Congress of Rheumatology meeting in San Diego 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Approximately 40 attendees from 18 different companies. Introduced the NHIR Translational Research Partnership to them. (Title: the NIHR Translational Research Partnership).

Several contacts subsequent to the meeting with potential collaborative research ensuing.
Year(s) Of Engagement Activity 2013
 
Description R&D conference. Health Research - partnerships for success 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact This was a conference at BMA House organised by ABPI, BIA and NOCRI - to explain largely to an industrial audience, how the collaborative landscape (Industry/academia) was evolving. Other speakers included Lord Howe and Sir John Savill. There were approximately 250 attendees.

New contacts from potential industrial collaborative partners
Year(s) Of Engagement Activity 2012
 
Description RA-MAP Biostatistics overview (presentation at MATURA meeting) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact RA-MAP Biostatistics Overview was presented by Brian Tom (RA-MAP statistician PI) at MATURA Scientific Meeting, where the statistical approaches used in RA-MAP were outlined, which may be relevant to the MRC Stratified Medicine Initiative MATURA consortium
Year(s) Of Engagement Activity 2017
 
Description RA-MAP Presentation at PSI Immunology Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact Brian Tom, the leading PI statistician of RA-MAP, provided RA-MAP project overview and statistical approaches taken in a presentation given at PSI (Promoting Statistical Insight) Immunology meeting to industry statisticians.
Year(s) Of Engagement Activity 2016
 
Description RA-MAP data infrastructure and analysis strategy presented at Wellcome Trust Immune Modulated Inflammatory Disease Workshop (Feb 2017) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact RA-Map data infrastructure and analysis strategy was presented
Year(s) Of Engagement Activity 2017
 
Description RA-MAP data infrastructure was presented as an exemlar at the MRC Stratified Medicine Applicats Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact RA-Map data infrastructure was presented as an exemplar at the MRC Stratified Medicine applicants workshop
Year(s) Of Engagement Activity 2017
 
Description RA-MAP project presentation as a Startified Medicine exemplar at the MRC-eMedLab Stratified Medicine Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The RA-Map project was presented as a Stratified Medicine exemplar at the MRC-eMedLab Stratified Medicine workshop
Year(s) Of Engagement Activity 2016
 
Description RA-MAP website 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact The RA-MAP website is currently hosted by Newcastle University but serves the needs of Consortium members - the numerous industry and academic partners making up the RA-MAP consortium.
Year(s) Of Engagement Activity 2017
URL http://research.ncl.ac.uk/ra-map/
 
Description RA/MAP Closure meeting (June 2017, London) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Closure of the RA MAP consortium with presentations on relevant outputs and future plans
Year(s) Of Engagement Activity 2017
 
Description RACE Scientific Advisory Board Meeting 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentations on TRAFIC and BIO-FLARE as worked examples of our experimental medicine approach.
Year(s) Of Engagement Activity 2016
 
Description RACE Second International Scientific Advisory Board Meeting, Glasgow, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact Scientific presentations and patient-focused discussions. Excellent feedback from the panel, which has influenced.renewal plans.
Year(s) Of Engagement Activity 2018
URL http://www.race-gbn.org/communityengagement/
 
Description RACE launch 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Participants in your research and patient groups
Results and Impact Interesting discussions, including with an Olympian

None yet
Year(s) Of Engagement Activity 2014
 
Description RT-CURE Annual Meeting, Beerse, 2018 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Study participants or study members
Results and Impact Annual meeting of the RT-CURE consortium. Excellent meeting with welcome patient partner participation.
Year(s) Of Engagement Activity 2018
 
Description Remission Accomplished - Houses of Parliament 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact There was an active discussion around the therapy of inflammatory arthritis and its future direction.

None yet
Year(s) Of Engagement Activity 2014
 
Description Research Engagement Poster Campaign 2015 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Poster campaign describing research in lay terms for public and patients audience. To promote engagement in research in the NE.

Public and patients expressed interest in participating in research.
Year(s) Of Engagement Activity 2015
 
Description Rheumatoid Arthritis Strategic Review, Newcastle, 2015 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Strategic realignment of research activities
Year(s) Of Engagement Activity 2015
 
Description Rheumatoid Arthritis: What's New? Karolinska, Sweden 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Novel and targeted RA treatments.
Year(s) Of Engagement Activity 2016
 
Description Rheumatology Research Patient Partnership (R2P2) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Education and empowernig Patient Partners to participate in research design and oversight.

Education and empowering Patient Partners to participate in research design and oversight. The Rheumatology Research Group in Birmingham recognise the importance of involvement of patients and members of the general public in all aspects of the research process, including initial project development and grant applications, the design and implementation of the studies as well as their dissemination.
Year(s) Of Engagement Activity 2014
URL http://www.birmingham.ac.uk/research/activity/mds/projects/ii/R2P2/index.aspx
 
Description Roche Systems Pharmacology Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact A systems approach to investigating drug response variability in RA
Year(s) Of Engagement Activity 2015
 
Description Royal College of Physicians of Edinburgh Therapeutic Drug Monitoring Conference, Edinburgh, 2018 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Workshop focussed on therapeutic drug monitoring for biologic therapies including round table discussion and establishment of a working group.
Year(s) Of Engagement Activity 2018
 
Description Seminar at Altnagelvin Hospital 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Patients, carers and/or patient groups
Results and Impact Prof Ian Bruce provided a seminar about pevention of RA based on PREVENT RA study.
Year(s) Of Engagement Activity 2015
 
Description Stockholm - RA: What's Next - 2016 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Invited Lecture
Year(s) Of Engagement Activity 2016
 
Description Stratified Medicine Meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Prospective collaborations
Year(s) Of Engagement Activity 2015
 
Description TACERA Premier 2 London 2016 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Hosted the day. Introductory Presentation.
Year(s) Of Engagement Activity 2016
 
Description TEDx Newcastle 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact It provided an opportunity to highlight the importance of patient participation in experimental medicine and translational research studies

The TEDx Newcastle website has received more than 10000 hits
Year(s) Of Engagement Activity 2014
URL http://www.greatneatcentre.com/2014/07/the-patient-who-changed-my-life-people.html
 
Description Translational Research Collaboration Steering Group Meeting (February 2018) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The quarterly TRC meetings help us to develop a strategy for the TRC and industry links including new SLE and RA studies/trials
Year(s) Of Engagement Activity 2018
 
Description UK Autoimmunity Workshop - Defining the Grand Challenges - Clinical Trials, New Therapeutics, Repurposing 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact JDRF
MRC
ARUK
WT
Year(s) Of Engagement Activity 2016
 
Description Visit to China to key universities (January 2018, China) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Our university visited 4 Chinese universities. We planned and discussed future collaborations including student exchanges, collaborative grants and future visits
Year(s) Of Engagement Activity 2018